Celsense

 

 

NEWS RELEASE - For Immediate Release

Celsense, Inc Board of Directors Elects Gregory T. Hebrank M.D. to Board

February 1, 2014 - Pittsburgh, Pennsylvania

The Board of Directors of Celsense, Inc. unanimously elected Gregory T. Hebrank, M.D. to the Board effective February 1, 2014. Dr. Hebrank is a co-founder and executive vice president of corporate operations and finance of Knopp Biosciences, LLC. He is also a member of the Board of Directors of LaunchCyte, LLC and a successful investor in both public and private biotechnology companies. Dr. Hebrank continues to practice medicine part time in Greensburg, Pennsylvania. He earned a B.S. in Biomedical Engineering from Vanderbilt University, an M.D. from Tulane University School of Medicine, and completed his residency training in Obstetrics and Gynecology at Magee-Women’s Hospital in Pittsburgh. Dr. Hebrank received his M.B.A. from Carnegie Mellon University.

“We are delighted to have Greg join our Board,” said Paul Kornblith, Chairman of the Board of Celsense. Dr. Hebrank, along with the rest of the Celsense Board will stand for election by the shareholders in April 2014.

About Celsense
Celsense, Inc. develops and offers novel pre-clinical and clinical-grade products that enable the non-invasive imaging of cells in vivo using MRI. The company’s lead product Cell Sense is a patented fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Cell Sense is the subject of a Drug Master File at US FDA and Health Canada, and is the only clinical grade MRI cell tracking reagent available in North America.  Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. Celsense’s mission is to be the standard for cellular imaging in human health.

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412)263-2870
charlie@celsense.com